The right pediatric program to deliver your medicine sooner.
Let expertise be your guide
Successfully navigating the road to developing and delivering pediatric products requires a specialized mix of scientific, therapeutic, regulatory and operational expertise to ensure your pediatric studies are successfully planned and executed.
From the earliest planning stages of clinical development, through launch and real-world assessment, pediatric expertise is key to ensuring you are asking the right questions to meet the specific needs of infants, children and adolescents.
364 pediatric studies
conducted across 101 countries between 2013 and 2018
From start to finish, we are here
At IQVIA, we are prepared to provide tailored, informed support throughout your journey. We can help
- Develop your product’s Pediatric Investigation Plan (PIP) and/or Pediatric Study Plan (PSP)
- Recommend alternative study designs through the use of modeling, simulation and real world data
- Navigate complex and unique regulatory requirements for pediatric clinical research
- Connect you to a network of specialized pediatric study sites
- Identify, consent/assent and retain pediatric patients and their families throughout your program
Pediatric Center of Excellence
Experts from across IQVIA come together to help you conceptualize and execute your pediatric studies. The group is charged with advising on the conduct of pediatric programs to ensure the right strategy and the right level of oversight, counsel, training and collaboration is applied to your project. Identify the right path to fulfill pediatric safety requirements and deliver a product that meets the unique needs of infants, children and adolescents, from trial environments into their everyday lives.
Advancing Pediatric Cancer Research
The RACE for Children Act will have significant impact on cancer drug development. Among all ongoing cancer trials, more than 70% involve RACE-defined molecular target drugs, but only 6.9% appear to include pediatric-age participants, according to a new analysis conducted by the IQVIA Institute.
Assess your protocol against real world evidence using advanced analytics, and reduce the risk of costly amendments.
Richer real world data insights can drive smarter decisions.
Bring trials directly to patients to improve access and engagement, increase quality and shorten timelines.